Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.39 |
| ▸ | USP2 | O75604 | 8/20 | 0.39 |
| ▸ | CASP1 | P29466 | 8/20 | 0.39 |
| ▸ | CASP7 | P55210 | 8/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.39 |
| ▸ | TSHR | P16473 | 5/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10019329 | 0.83 | CYP1A2 (0.43) | NPC1RAB9ASMN1; SMN2L3MBTL1CYP1A2 | |
| SCHEMBL10019304 | 0.82 | NPC1 (0.44) | NPC1RAB9ACYP1A2CYP2C19CYP2D6 | |
| SCHEMBL10019309 | 0.79 | CLK4 (0.48) | SMN1; SMN2CYP1A2TSHRMAPK1CYP2C19 | |
| SCHEMBL10019314 | 0.79 | TUBB4A (0.61) | NPC1RAB9ASMN1; SMN2TDP1CYP1A2 | |
| SCHEMBL10019301 | 0.78 | MET (0.51) | CYP1A2USP2CASP1CASP7CYP3A4 | |
| SCHEMBL10019319 | 0.78 | MAPT (0.46) | NPC1CYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL10019308 | 0.78 | ACHE (0.46) | NPC1RAB9ASMN1; SMN2TDP1CYP3A4 | |
| SCHEMBL10019337 | 0.77 | CYP1A2 (0.43) | PTGER3L3MBTL1CYP1A2ALDH1A1MEN1 | |
| SCHEMBL10019312 | 0.76 | APP (0.42) | CYP1A2USP2CASP1CASP7CYP3A4 | |
| SCHEMBL650405 | 0.76 | TUBB4A (0.66) | PKML3MBTL1CYP1A2USP2CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119683-B2 | Aryl substituted sulfonamide compounds and their use as anticancer agents | TAIPEI MEDICAL UNIVERSITY (TW) | 2012-02-21 | — | — | US | disclosed |
| US-20110039880-A1 | ARYL SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | TAIPEI MEDICAL UNIVERSITY (TW) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039880-A1 | ARYL SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | ARSA, SULT1E1, STS | PTGER3 3354/4885NPC1 2235/4885RAB9A 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.